Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.

摘要: The aim of this prospective phase II study was to evaluate the tumor response neuroendocrine tumors high-dose targeted irradiation with 7.4 GBq/m2 radiolabeled somatostatin analog 90Y-1,4,7,10-tetra-azacyclododecan-4,7,10-tricarboxy-methyl-1-yl-acetyl-d-Phe-Tyr3-octreotide (DOTATOC). In addition, we investigated clinical benefit 90Y-DOTATOC regarding malignant carcinoid syndrome and tumor-associated pain. Methods: Thirty-nine patients (mean age, 55 y) progressive gastroenteropancreatic bronchial were included. treatment consisted 4 equal intravenous injections a total GBq/m290Y-DOTATOC, administered at intervals 6 wk. After each cycle, standardized assessment using National Cancer Institute grading criteria (NCI-CTC) performed. Results: objective rate according World Health Organization (WHO) 23%. For endocrine pancreatic (13 patients), 38%. Complete remissions found in 5% (2/39), partial 18% (7/39), stable disease 69% (27/39), 8% (3/39). A significant reduction symptoms could be 83% diarrhea, 46% flush, 63% wheezing, 75% pellagra. overall 63%. All responses (both WHO response) ongoing for duration follow-up (median, mo; range, 2–12 mo). Side effects grade 3 or lymphocytopenia 23%, anemia 3%, 2 renal insufficiency 3%. Conclusion: High-dose radiotherapy GBq/m290Y-DOTATOC is well-tolerated tumors, remarkable response.